Trial Profile
Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs AV-GBM-1 (Primary) ; Antineoplastics; Granulocyte macrophage colony stimulating factor
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Biomarker; Therapeutic Use
- Sponsors AiVita Biomedical
- 06 Jun 2023 Final results of phase 2 trial presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 04 Oct 2022 Results presented in an AiVita Biomedical Media Release.
- 04 Oct 2022 Status changed from active, no longer recruiting to completed, according to an AiVita Biomedical media release.